Pancreatic Cancer Research

ResearcherGunma UniversityActive in the last 2 years

Takamichi Igarashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9077-2052; OpenAlex author ID A5000126494. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 14

  1. Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon-Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement. Co-author DOI 10.1002/ags3.70259↗
  2. Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of… Co-author DOI 10.1002/ags3.70270↗
  3. CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1002/ags3.70275↗
  4. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. First author DOI 10.1245/s10434-026-20728-8↗
  5. Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involv… Co-author DOI 10.1007/s12328-025-02175-2↗
  6. Impact of Preoperative Weight Loss on Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/biomedicines13071703↗
  7. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peri… Co-author DOI 10.1002/ags3.12719↗
  8. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreati… Co-author DOI 10.1002/ags3.12613↗
  9. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001537↗
  10. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Co-author DOI 10.1245/s10434-019-07708-x↗
  11. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Co-author DOI 10.1111/cas.13847↗
  12. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12307↗
  13. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Co-author DOI 10.18632/oncotarget.14703↗
  14. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Co-author DOI 10.18632/oncotarget.22634↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Araki · 10 shared papers, 2017–2026 · strength 1.54
  2. Mariko Tsukagoshi · 10 shared papers, 2017–2026 · strength 1.54
  3. Ken Shirabe · 10 shared papers, 2017–2026 · strength 1.54
  4. Kei Hagiwara · 6 shared papers, 2018–2026 · strength 0.86
  5. Norihiro Ishii · 7 shared papers, 2017–2026 · strength 0.74
  6. Nana Kimura · 3 shared papers, 2024–2026 · strength 0.69
  7. Takehiko Yokobori · 6 shared papers, 2017–2026 · strength 0.63
  8. Tsutomu Fujii · 3 shared papers, 2023–2025 · strength 0.63
  9. Ryosuke Fukushima · 2 shared papers, 2025–2026 · strength 0.52
  10. Takaomi Seki · 2 shared papers, 2025–2026 · strength 0.51
  11. Katsuhisa Hirano · 2 shared papers, 2025–2026 · strength 0.48
  12. Takahiro Yamanaka · 6 shared papers, 2017–2020 · strength 0.46
  13. Akira Watanabe · 6 shared papers, 2017–2020 · strength 0.46
  14. Ayaka Itoh · 2 shared papers, 2024–2025 · strength 0.45
  15. Mina Fukasawa · 2 shared papers, 2024–2025 · strength 0.45
  16. Norifumi Harimoto · 4 shared papers, 2018–2020 · strength 0.34
  17. Tatsuya Ohno · 1 shared paper, 2026 · strength 0.29
  18. Masahiko Okamoto · 1 shared paper, 2026 · strength 0.29
  19. Hiroyuki Kuwano · 4 shared papers, 2017–2019 · strength 0.26
  20. Shimpei Maeda · 1 shared paper, 2026 · strength 0.23
  21. Masahiro Iseki · 1 shared paper, 2026 · strength 0.23
  22. Masamichi Mizuma · 1 shared paper, 2026 · strength 0.23
  23. Kyohei Ariake · 1 shared paper, 2026 · strength 0.23
  24. Shuichi Aoki · 1 shared paper, 2026 · strength 0.23
  25. Michiaki Unno · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.